Compare · IQV vs JNJ
IQV vs JNJ
Side-by-side comparison of IQVIA Holdings Inc. (IQV) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. IQV focuses on Biotechnology: Commercial Physical & Biological Resarch, while JNJ focuses on Biotechnology: Pharmaceutical Preparations.
- JNJ is the larger of the two at $640.02B, about 14.9x IQV ($43.09B).
- Over the past year, IQV is up 40.9% and JNJ is up 49.7% - JNJ leads by 8.8 points.
- JNJ has been more active in the news (11 items in the past 4 weeks vs 6 for IQV).
- Both have 25 recent analyst ratings on file.
- Company
- IQVIA Holdings Inc.
- Johnson & Johnson
- Price
- $262.02+1.82%
- $265.69-0.25%
- Market cap
- $43.09B
- $640.02B
- 1M return
- +8.39%
- +1.89%
- 1Y return
- +40.88%
- +49.70%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2013
- News (4w)
- 6
- 11
- Recent ratings
- 25
- 25
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest IQV
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Pricing of Senior Notes
- IQVIA Announces Offering of Senior Notes
- Officer Berkshire James G. exercised 5,381 shares at a strike of $131.82, sold $697,228 worth of shares (2,668 units at $261.33) and returned $709,558 worth of shares to the company (2,713 units at $261.54) (SEC Form 4)
- IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
- IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
- IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
- IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
- Officer Staub W Richard sold $1,279,740 worth of shares (5,500 units at $232.68), decreasing direct ownership by 29% to 13,312 units (SEC Form 4)
- Officer Patel Bhavik sold $436,426 worth of shares (1,855 units at $235.27), decreasing direct ownership by 58% to 1,348 units (SEC Form 4)
Latest JNJ
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director Hewson Marillyn A
- Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
- Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
- EVP, WW Chair, MedTech Schmid Timothy exercised 33,597 shares at a strike of $144.99 and sold $9,230,440 worth of shares (33,597 units at $274.74) (SEC Form 4)
- Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
- UBS resumed coverage on Johnson & Johnson with a new price target
- New insider Cavanaugh Thomas claimed ownership of 499 shares (SEC Form 3)
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results